お知らせ • May 21
Vaxart, Inc., Annual General Meeting, Jul 16, 2026 Vaxart, Inc., Annual General Meeting, Jul 16, 2026. お知らせ • Apr 25
Vaxart, Inc. Appoints James Breitmeyer, M.D., Ph.D., to Board of Directors Vaxart, Inc. announced the appointment of James Breitmeyer, M.D., Ph.D., to its Board of Directors. Dr. Breitmeyer brings more than 35 years of biopharmaceutical experience, having led clinical development programs resulting in eight FDA product approvals and numerous regulatory successes across the United States, Europe, and Japan. In February 2026, he joined Altay Therapeutics as CEO and Board Director, directing the advancement of the company’s pipeline of oral transcription factor therapies. He most recently served as the President and CEO of Oncternal Therapeutics, Inc., where he oversaw the clinical development of a diverse pipeline of first-in-class oncology assets. He also brings vaccine development expertise from his previous role as President of Bavarian Nordic, Inc., where he oversaw the development of cancer, infectious disease, and bioterrorism vaccines. Additionally, Dr. Breitmeyer held senior clinical leadership roles at Eli Lilly and Company and Cadence Pharmaceuticals, where he managed the transition of multiple candidates through the clinical and regulatory process toward successful commercial launch. His board experience includes previous director roles at Zogenix, Inc. and Otonomy, Inc., where he served on Audit and Compensation Committees. Previously, he held the position of President at Bavarian Nordic, Inc. and served as Executive Vice President and Chief Medical Officer at Cadence Pharmaceuticals. Dr. Breitmeyer also served as Vice President of Biotechnology at Eli Lilly and Company, where he was responsible for the corporate biotechnology pipeline. Earlier in his career, he held senior leadership roles at Applied Molecular Evolution and Serono Laboratories, where he led the development of therapies resulting in FDA approvals for Rebif® and Serostim®. Dr. Breitmeyer earned his M.D. and Ph.D. from Washington University School of Medicine. He completed postdoctoral fellowships at Harvard Medical School and the Dana-Farber Cancer Institute, where he also served as a clinical instructor. お知らせ • Sep 03
Vaxart, Inc. Announces Retirement of Michael J. Finney from the Board of Directors and Science and Technology Committee, Effective September 30, 2025 Vaxart, Inc. announced that its Chairman, Michael J. Finney, Ph.D., has announced his retirement from the Company's Board of Directors and Science and Technology Committee after a distinguished tenure of service. His retirement will be effective September 30, 2025. The Board of Directors will meet this month to discuss Board leadership, Board composition and other governance issues, taking into account stockholder feedback, with the goal of continuing to advance the Company’s scientific progress. お知らせ • Apr 03
Vaxart, Inc., Annual General Meeting, May 21, 2025 Vaxart, Inc., Annual General Meeting, May 21, 2025. お知らせ • Jan 30
Vaxart, Inc. Announces Board and Committee Changes Vaxart, Inc. announced the appointment of Kevin Finney to the Company’s Board of Directors, effective January 28, 2025. Mr. Finney is a seasoned healthcare executive and experienced board member who brings decades of industry leadership experience and operational expertise. Mr. Finney will serve as a member of the Audit and Nominating and Governance Committees of the Board. The Company also announced that Robert A. Yedid has stepped down from the Board of Directors, effective January 28, 2025. About Kevin Finney: Mr. Finney is an experienced biotech executive and director who has held numerous leadership roles in the healthcare industry, leading companies from early stages of development through commercialization. Mr. Finney currently serves as President and Chief Executive Officer of Autobahn Therapeutics and Chairman of its Board of Directors since 2019. Prior to joining Autobahn, Mr. Finney served as President, Chief Operating Officer, and a Director of Abide Therapeutics through the company’s acquisition by Lundbeck in 2019. Prior to this, Mr. Finney founded and served as the Chief Operating Officer of Zavante Therapeutics through the company’s acquisition by Nabriva Therapeutics in 2018. Mr. Finney previously spent a decade as Head of World-Wide Corporate Development at Allergan, Inc. Prior to Allergan, Mr. Finney held executive management roles at Prometheus Laboratories, Inc. (now Nestle Health Science), Amylin Pharmaceuticals, Inc. (now Bristol-Myers Squibb) and the Parke-Davis division of Warner-Lambert (now Pfizer). In addition to his role at Autobahn, Mr. Finney serves on the board of Eirion Therapeutics, and previously served on the boards of Elsie Biotechnologies (now GSK), Taris Biomedical (now J&J) and Anterios (now Allergan). Mr. Finney holds an MBA from the George L. Graziado School of Business, Pepperdine University, and a B.A. in exercise physiology from California State University Long Beach. Kevin Finney and Vaxart Board Chairman Dr. Michael J. Finney are not related. Mr. Finney was also appointed as a member of the Audit Committee and the Nominating and Governance Committee of the Board. On January 24, 2025, the Board also appointed Elaine J. Heron, Ph.D. as a member of the Compensation Committee of the Board, effective January 28, 2025. Recent Insider Transactions • Jun 21
Independent Director recently bought Mex$250k worth of stock On the 18th of June, William Watson bought around 20k shares on-market at roughly Mex$12.48 per share. This transaction amounted to 62% of their direct individual holding at the time of the trade. This was the largest purchase by an insider in the last 3 months. This was the only on-market transaction from insiders over the last 12 months.